← Leaderboards
Salah-Uddin Ahmed
University Of Michigan At Ann Arbor
$5,934,074
Attributed
$5,934,074
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,934,074 · 6
By mechanism
R01$4,966,057 · 3
R21$744,938 · 2
R03$223,079 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Rheumatoid Arthritis”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Lionel B Ivashkiv · Hospital For Special Surgery$38,096,851
- Paul M. Ridker · Brigham And Women'S Hospital$34,275,148
- V Michael Holers · University Of Colorado Denver$28,178,502
- Michael B Brenner · Brigham And Women'S Hospital$26,598,289
- Betty Diamond · Feinstein Institute For Medical Research$20,428,564
Research focus
Rheumatoid ArthritisFibroblastsRegulationProductionEnzymesSuccessSignal TransductionRattusInterleukin-6SeveritiesTissuesInflammationAdjuvant ArthritisCytokineIn VitroInflammatoryJointsMediatingAnti-Inflammatory AgentsChronicEfficacy TestingSignal PathwayIn VivoNovel Therapeutics
Grant awards (22)
Molecular mechanisms of TAK1 regulation in rheumatoid arthritis$1,407,925
R01 · FY2025 · AR · contact PI
MicroRNA-based therapy for rheumatoid arthritis$335,650
R01 · FY2022 · AR · contact PI
MicroRNA-based therapy for rheumatoid arthritis$329,110
R01 · FY2021 · AR · contact PI
MicroRNA-based therapy for rheumatoid arthritis$153,000
R01 · FY2021 · AR · contact PI
MicroRNA-based therapy for rheumatoid arthritis$346,081
R01 · FY2020 · AR · contact PI
MicroRNA-based therapy for rheumatoid arthritis$349,094
R01 · FY2019 · AR · contact PI
MicroRNA-based therapy for rheumatoid arthritis$349,094
R01 · FY2018 · AR · contact PI
Regulation of IL-6 mediated inflammation and tissue destruction by EGCG$377,341
R01 · FY2017 · AR · contact PI
Novel Targeted Therapeutics for Regulating Synovial Hyperplasia in RA$168,208
R21 · FY2017 · AR · contact PI
Regulation of IL-6 mediated inflammation and tissue destruction by EGCG$326,740
R01 · FY2016 · AR · contact PI
Novel targeted therapeutics for regulating synovial hyperplasia in RA$200,530
R21 · FY2016 · AR · contact PI
RANTES/CCL5 mediated tissue remodeling in RA$31,947
R01 · FY2016 · AR · contact PI
Regulation of IL-6 mediated inflammation and tissue destruction by EGCG$320,875
R01 · FY2015 · AR · contact PI
Regulation of IL-6 mediated inflammation and tissue destruction by EGCG$320,875
R01 · FY2014 · AR · contact PI
Regulation of IL-6 mediated inflammation and tissue destruction by EGCG$318,325
R01 · FY2013 · AR · contact PI
Inhibition of CCR1/CCR5 mediated angiogenesis and joint destruction by EGCG$72,023
R03 · FY2010 · AR · contact PI
Inhibition of CCR1/CCR5 mediated angiogenesis and joint destruction by EGCG$66,404
R03 · FY2009 · AR · contact PI
Inhibition of CCR1/CCR5 mediated angiogenesis and joint destruction by EGCG$8,652
R03 · FY2009 · AR · contact PI
Inhibition of RA synovial fibroblasts invasion by green tea polyphenols$180,435
R21 · FY2008 · AT · contact PI
Inhibition of CCR1/CCR5 mediated angiogenesis and joint destruction by EGCG$76,000
R03 · FY2008 · AR · contact PI
Inhibition of RA synovial fibroblasts invasion by green tea polyphenols$5,765
R21 · FY2008 · AT · contact PI
Inhibition of RA synovial fibroblasts invasion by green tea polyphenols$190,000
R21 · FY2007 · AT · contact PI